Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21051198 | 0.87 | P2RX7 (0.43) | MEN1KMT2AMAPTP2RX7L3MBTL1 | |
| SCHEMBL21051197 | 0.87 | P2RX7 (0.43) | MEN1KMT2AMAPTP2RX7L3MBTL1 | |
| SCHEMBL21051196 | 0.87 | P2RX7 (0.43) | MEN1KMT2AMAPTP2RX7L3MBTL1 | |
| SCHEMBL19839203 | 0.84 | MEN1 (0.46) | MEN1KMT2AMAPTCCR5L3MBTL1 | |
| SCHEMBL26426413 | 0.84 | HSD17B10 (0.37) | MEN1KMT2A | |
| SCHEMBL19839541 | 0.80 | MEN1 (0.38) | MEN1KMT2AMAPTP2RX7CCR5 | |
| SCHEMBL19839539 | 0.80 | MEN1 (0.38) | MEN1KMT2AMAPTP2RX7CCR5 | |
| SCHEMBL21104754 | 0.76 | MEN1 (0.48) | MEN1KMT2AMAPTP2RX7CCR5 | |
| SCHEMBL26089141 | 0.76 | CRBN (0.38) | MEN1KMT2AMAPTCCR5GPR119 | |
| SCHEMBL19839394 | 0.76 | DDB1 (0.39) | MEN1KMT2AMAPTCCR5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | MEN1 2365/4885KMT2A 1591/4885MAPT 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.